FOLH1 and metastatic neoplasm: This finding could be related to the presence of lower tumor-burden, that might be reflected by the presence of micro-metastatic disease not detectable by molecular imaging (negative PSMA-PET) and thus probably defining a population at lower-risk of developing clinically relevant events at mid-term follow-up.